Stockscreener 앱 받기
3.25
7.41%
-0.26
시장 영업 전:
3.30
0.05
+1.54%
Immuneering Corp 주식(IMRX)의 최신 뉴스
Using Python tools to backtest Immuneering Corporation strategiesReal-Time Signal Tracking with Entry Level - Newser
Is Immuneering Corporation showing signs of accumulationFree Trend Analysis for Safer Trades - Newser
Should you hold or exit Immuneering Corporation nowTrading Watchlist with Real Time Filters - Newser
Applying chart zones and confluence areas to Immuneering CorporationFree Trade Setups With Clear Risk Limits - Newser
Is Immuneering Corporation stock entering bullish territoryAI Volatility Forecast and Risk Monitor - Newser
Is this a good reentry point in Immuneering CorporationIntraday Movement Recap and Chart Summary - Newser
Quant Tools Rank Immuneering Corporation as High Risk High RewardStep-by-Step Trade Signal Implementation Guide Ready - metal.it
Is it the right time to buy Immuneering Corporation stockExtraordinary earning power - Jammu Links News
What drives Immuneering Corporation stock priceGet high-impact stock recommendations now - Jammu Links News
How many analysts rate Immuneering Corporation as a “Buy”Build a diversified portfolio for maximum returns - Jammu Links News
What are Immuneering Corporation company’s key revenue driversExceptional stock performance - Jammu Links News
Multi asset correlation models including Immuneering CorporationFree Multi-Bagger Potential Stock Forecast Tools - Newser
How does Immuneering Corporation compare to its industry peersStock Strategy Entry Points Backed By Experts - Jammu Links News
Real time breakdown of Immuneering Corporation stock performanceStrong Buy Opportunity with Volume Support - Newser
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
How Efficient Is Immuneering Corporation at Controlling Operating CostsFree Trade Timing Strategy With Technical Data - Newser
Immuneering Corporation’s Price Action Aligns with Quant SignalsConsistent Income Focused Trade List Analyzed - metal.it
Published on: 2025-07-28 06:27:12 - Jammu Links News
What makes Immuneering Corporation stock price move sharplyProven High Yield Signals - metal.it
How strong is Immuneering Corporation company’s balance sheetBreakout profit opportunities - Jammu Links News
What analysts say about Immuneering Corporation stockAccelerated wealth expansion - PrintWeekIndia
Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25 - Defense World
Is Immuneering Corporation a good long term investmentSuperior stock growth - jammulinksnews.com
Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser
Immuneering Corporation Rings the Closing Bell - Nasdaq
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan
Immuneering Corporation shares rise 10.63% intraday after receiving U.S. composition of matter patent for atebimetinib. - AInvest
The MEK effect on cancer — a slow and steady approach to drug resistance - PharmaVoice
Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa
Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa
Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com
Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus
Immuneering (IMRX) Soars 10.66% on Positive Trial Data, Insider Buying - AInvest
At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - stocksregister.com
Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data - Investing.com
Insider Buying: Brett Hall Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus
Immuneering (IMRX) CBO Brakewood buys $4804 in shares - Investing.com
Immuneering (IMRX) director Feinberg buys $63k in shares - Investing.com
Immuneering (IMRX) CEO Zeskind buys $50k+ in shares - Investing.com
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients - Pipelinereview
Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus
Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus
Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX
Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX
Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus
Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com
Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Asianet Newsable
0.24%
3.39%
자본화:
|
볼륨(24시간):